ZBTB16 and acute myeloid leukemia: Indeed, in ZBTB16‐RARA+AML, it has previously shown that ATRA degrades the abnormal fusion protein, but does not induce response, demonstrating that the oncoprotein loss is not sufficient to induce differentiation or clinical response.23, 24, 25, 26